Results 171 to 180 of about 52,183 (303)

Drug Eruptions

International Journal of Clinical Practice, 1968
openaire   +2 more sources

scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions

Journal of the European Academy of Dermatology and Venereology, EarlyView.
CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu, Agata Kurowski, Malini P. Naidu, Jonas Adalsteinsson, Shane A. Meehan, Natalia Alkon, Lauren R. Port, Sumanth Chennareddy, Emry R. Cohenour, Grace Christensen, Jonah Shulman, Nicholas Gulati, Constanze Jonak, Patrick M. Brunner   +13 more
wiley   +1 more source

Drug eruptions.

Journal of Nippon Medical School, 1987
openaire   +3 more sources

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions. [PDF]

World Allergy Organ J
James F, Goh MS, Vogrin S, Ng I, Douglas AP, Holmes NE, Chua KY, De Luca J, Sharma P, Zubrinich C, Aung AK, Gin D, Lambros B, Baker C, Foley P, Chong AH, Thien F, Fok JS, Su J, Scardamaglia L, Awad A, Tong S, Johnson D, Godsell J, Arasu A, Barnes S, Ojaimi S, Mar A, Yun J, Ange N, Tong WWY, Carr A, Loprete J, Katelaris CH, Slape D, Keat K, West TA, Lee M, Smith W, Hissaria P, Sidhu S, Janson S, Venkatesan S, Davies J, Lane MJ, Redmond AM, Robertson I, Legg A, Fernando S, Boyle T, Li J, Phillips EJ, Cleland H, Kern JS, Trubiano JA.   +54 more
europepmc   +1 more source

Dermatology 2.0: Precision medicine for inflammatory skin diseases

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Digital immune mapping of transcriptomics profiles from inflammatory skin disease biopsies enables precise molecular diagnosis, quantification of immune modules and personalized therapy selection by matching dominant immune signatures to targeted treatments.
Jeremy Di Domizio, Antoine Girardin, Curdin Conrad, Teofila Seremet, Michel Gilliet   +4 more
wiley   +1 more source

Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. [PDF]

J Am Acad Dermatol, 2018
Phillips GS, Freites-Martinez A, Hsu M, Skripnik Lucas A, Barrios DM, Ciccolini K, Marchetti MA, Deng L, Myskowski PL, Lee EH, Markova A, Lacouture ME.   +11 more
europepmc   +1 more source

Cell Therapy for Periodontal, Soft‐Tissue, and Craniofacial Regeneration

Journal of Periodontal Research, EarlyView.
The clinical translation of mesenchymal stem/stromal cells (MSCs) represents a major advancement in dentistry, especially for periodontal, soft‐tissue, and craniofacial regeneration. However, several challenges remain to be addressed, including the absence of standardised protocols, limited scalability, regulatory hurdles, a lack of well‐controlled ...
Kamal Mustafa, Shuntaro Yamada, Nerea Sanchez, Magdalena Mayol, Cecilie Gjerde, Mariano Sanz   +5 more
wiley   +1 more source

Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) [PDF]

, 2008
Arnold, A., Bircher, A., Haeusermann, P.
core   +1 more source

Fixed Drug Eruptions Due To/Caused by Levocetirizine and Cetirizine: An Uncommon Adverse Cutaneous Drug Reaction to Commonly Used Piperazine Derivatives. [PDF]

Indian Dermatol Online J
Tyagi M, Ahuja R, Patel V, Sahni K, Taneja N, Gupta S.   +5 more
europepmc   +1 more source